Who Paid My Doc
Yu Wang
Epilepsy Ann Arbor, MI Medical Doctor
NPI 1992027809 CMS profile 1342635
1500 E Medical Center Dr, Ann Arbor, MI 48109
General payments
$131
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Yu Wang of Ann Arbor, MI is reported in the CMS Open Payments database as having received $131 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 14th percentile of Epilepsy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $131 | 1 |
Beside peers
- Yu Wang
- Epilepsy median
- Middle half of Epilepsy
- National median
In program year 2025, general payments to Yu Wang were reported at $0. Among 324 Epilepsy profiles paid that year, the median was $366 and the middle half received between $146 and $1,396.
Show as a table
| Year | Yu Wang | Epilepsy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $280 | $104–$1,161 | $163 |
| 2020 | $0 | $148 | $53–$3,065 | $114 |
| 2021 | $0 | $202 | $56–$1,377 | $132 |
| 2022 | $0 | $294 | $112–$1,733 | $149 |
| 2023 | $0 | $313 | $118–$1,315 | $160 |
| 2024 | $131 | $338 | $131–$1,210 | $164 |
| 2025 | $0 | $366 | $146–$1,396 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
642
Drug cost
$552,428
Branded share of claims
48.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lamictal Xr Lamotrigine | Brand | 63 | $128,011 | |
| Xcopri Cenobamate | Brand | 41 | $81,166 | |
| Aptiom Eslicarbazepine Acetate | Brand | 15 | $68,180 | |
| Keppra Levetiracetam | Brand | 29 | $60,805 | |
| Onfi Clobazam | Brand | 11 | $50,052 | |
| Epidiolex Cannabidiol (Cbd) | Brand | 13 | $43,679 | |
| Briviact Brivaracetam | Brand | 24 | $33,291 | |
| Zonegran Zonisamide | Brand | 15 | $31,456 | |
| Nayzilam Midazolam | Brand | 11 | $10,787 | |
| Lamictal Lamotrigine | Brand | 14 | $10,464 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 8 billing codesPaid by Medicare
$6,977
Medicare patients
44
Services billed
116
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Depression | 59% | |
| Chronic kidney disease | 48% | |
| Diabetes | 41% | |
| Alzheimer's or dementia | 36% | |
| Atrial fibrillation | 34% | |
| Arthritis | 34% | |
| Ischemic heart disease | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Epilepsy in Michigan
Related records
Epilepsy in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Epilepsy
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.